PTC Therapeutics Inc

14. Sept. 2026, 20:08 UTC

Leerink has initiated coverage on PTC Therapeutics with an Outperform rating and a $98.00 price target, supporting a higher trading session since Friday's close.

11. Sept. 2026, 19:56 UTC

PTC Therapeutics Inc shares are lower today amid discussions from an investor event and plans for a Biologics License Application for a Fabry disease treatment.

10. Sept. 2026, 23:41 UTC

PTC Therapeutics Inc shares are higher in after-market trading, gradually increasing since Thursday's close, despite remaining below their 20-day moving average.

8. Sept. 2026, 20:07 UTC

Shares lower amid decline in iShares Biotechnology ETF.

2. Sept. 2026, 20:08 UTC

PTC Therapeutics Inc. is gaining today, supported by a broader advance in biotechnology stocks, despite a pullback earlier in the session.

31. Aug. 2026, 19:46 UTC

PTC Therapeutics shares are lower today, continuing a recent decline amid broader market unease following hawkish comments from Federal Reserve Chair Kevin Warsh.

28. Aug. 2026, 23:36 UTC

PTC Therapeutics Inc shares are higher in after-market hours, recovering from an earlier dip. No specific news was identified to explain the movement.

27. Aug. 2026, 20:07 UTC

PTC Therapeutics shares are lower today, continuing a decline since Wednesday's close, despite positive labor market data. No specific news was identified.

25. Aug. 2026, 20:09 UTC

PTC Therapeutics shares are higher as the company announces multiple data presentations for Sephience™ at an upcoming symposium in Helsinki.

24. Aug. 2026, 19:56 UTC

PTC Therapeutics shares rise as new data shows Sephience treatment significantly reduces blood phenylalanine levels in patients with phenylketonuria.

21. Aug. 2026, 19:26 UTC

PTC Therapeutics shares are lower today, trading near the lower end of their one-month range amid a broader market rebound in safe-haven assets.

20. Aug. 2026, 20:02 UTC

PTC Therapeutics shares are lower amid significant downward pressure on biotechnology stocks. The stock remains below its 20-day moving average.

19. Aug. 2026, 19:46 UTC

PTC Therapeutics is acquiring the ST-920 gene therapy asset for $111 million, including potential milestone payments, as shares trade higher since Tuesday's close.

18. Aug. 2026, 19:36 UTC

PTC Therapeutics Inc shares are lower amid cautious market sentiment influenced by rising treasury yields and inflation concerns. No specific news was identified for the decline.

14. Aug. 2026, 19:46 UTC

PTC Therapeutics shares are lower, reflecting broader market sentiment after U.S. retail sales unexpectedly declined in July. The stock is below its 20-day moving average.

13. Aug. 2026, 19:36 UTC

PTC Therapeutics announced the acquisition of ST-920 for $111 million. Shares are lower amid ongoing bearish trends, despite Wells Fargo's Overweight rating and $109 price target.

12. Aug. 2026, 23:51 UTC

PTC Therapeutics acquires ST-920 gene therapy for $111 million, enhancing its rare disease portfolio. Shares are higher in after-market hours.

11. Aug. 2026, 19:46 UTC

PTC Therapeutics Inc is trading lower amid market adjustments following last Friday's weak jobs report and ahead of upcoming U.S. inflation data releases.

10. Aug. 2026, 19:46 UTC

PTC Therapeutics shares are higher today amid broader market uncertainty regarding the Federal Reserve's interest rate policy following last week's employment report.

7. Aug. 2026, 21:02 UTC

PTC Therapeutics Inc shares are lower in after-market hours, reversing a trend of higher finishes over the past five sessions. No specific news was identified.

6. Aug. 2026, 19:56 UTC

PTC Therapeutics Inc. is higher today, having reached a peak earlier in the session. No specific news was identified to explain the price action.

5. Aug. 2026, 19:26 UTC

PTC Therapeutics Inc. will participate in upcoming investor conferences. Shares are lower today, remaining near the lower end of their one-month range.

4. Aug. 2026, 20:07 UTC

PTC Therapeutics shares are higher today, buoyed by positive market sentiment amid a significant decline in crude oil prices.

3. Aug. 2026, 19:46 UTC

PTC Therapeutics reported second-quarter revenue of $360.52 million and raised its full-year outlook to $1.18 billion to $1.28 billion, with shares advancing today.

31. Juli 2026, 21:01 UTC

PTC Therapeutics Inc shares rose in after-market trading, despite broader market concerns over inflation and interest rates amid rising crude oil prices.

30. Juli 2026, 22:31 UTC

PTC Therapeutics raised its 2026 revenue guidance after reporting strong Q2 results, with EPS of $0.92 exceeding estimates. Shares are higher in after-market trading.

29. Juli 2026, 18:26 UTC

PTC Therapeutics Inc shares are lower today, reflecting a broader decline. Market participants await the Federal Reserve's interest rate decision this afternoon.

28. Juli 2026, 18:31 UTC

PTC Therapeutics shares are lower as analysts anticipate a 5.6% revenue decline in Q2, contrasting with last year's growth of 24.2%.

27. Juli 2026, 20:06 UTC

PTC Therapeutics Inc shares are lower today amid broader market declines, influenced by falling oil prices and Treasury yields ahead of the Federal Reserve meeting.

22. Juli 2026, 17:16 UTC

PTC Therapeutics shares are lower today, trading near the lower end of their one-month range amid rising crude oil prices affecting the broader market.